Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neutral endopeptidase modulates neurogenic inflammation.

J A Nadel1

  • 1Cardiovascular Research Institute, University of California, San Francisco 94143-0130.

The European Respiratory Journal
|June 1, 1991
PubMed
Summary

Neutral endopeptidase (NEP) regulates airway inflammation by inactivating neuropeptides. Inhibiting NEP or exposure to irritants exaggerates neurogenic inflammation, while administering NEP reduces it.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optogenetic stimulation of striatal patches modifies habit formation and inhibits dopamine release.

Scientific reports·2021
Same author

Respiratory syncytial virus activates epidermal growth factor receptor to suppress interferon regulatory factor 1-dependent interferon-lambda and antiviral defense in airway epithelium.

Mucosal immunology·2018
Same author

Plugging (publicising) to prevent mucous plugging.

The European respiratory journal·2010
Same author

Alternative mechanisms for tiotropium.

Pulmonary pharmacology & therapeutics·2009
Same author

Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases.

The European respiratory journal·2008
Same author

Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease.

Respiratory medicine·2007

Area of Science:

  • Pulmonary Medicine
  • Neuroimmunology
  • Enzymology

Background:

  • A noncholinergic, nonadrenergic nervous system in airways releases neuropeptides upon irritation.
  • Neuropeptides trigger responses like cough, mucus secretion, and smooth muscle contraction, collectively termed neurogenic inflammation.
  • Neutral endopeptidase (NEP) is an enzyme on lung cells that inactivates these neuropeptides, limiting inflammatory responses.

Purpose of the Study:

  • To investigate the role of neutral endopeptidase (NEP) in regulating neurogenic inflammation in the airways.
  • To explore factors that inhibit NEP and exacerbate neurogenic inflammation.
  • To assess the therapeutic potential of NEP modulation in airway inflammatory conditions.

Main Methods:

  • Review of existing literature on airway neurogenic inflammation and neutral endopeptidase (NEP).
  • Analysis of studies involving pharmacological NEP inhibition and exposure to irritants (e.g., cigarette smoke, toluene diisocyanate).
  • Examination of data on the effects of exogenous NEP administration and corticosteroid treatment on neurogenic inflammation.

Main Results:

  • NEP inhibition, cigarette smoke, viral infections, and toluene diisocyanate exposure lead to exaggerated neurogenic inflammatory responses.
  • Administration of exogenous human recombinant NEP effectively inhibits neurogenic inflammation.
  • Corticosteroids suppress neurogenic plasma extravasation and can upregulate NEP in human airway tissue.

Conclusions:

  • Neutral endopeptidase (NEP) plays a critical role in limiting neurogenic inflammation in the airways.
  • Dysregulation of NEP activity contributes to exaggerated inflammatory responses in various respiratory conditions.
  • Targeting NEP or modulating its activity presents a potential therapeutic strategy for managing airway inflammation.

Related Experiment Videos